Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Identification and characterization of the binding sequences and target genes of p53 lacking the 1st transactivation domain.

Suzuki S, Tsutsumi S, Chen Y, Ozeki C, Okabe A, Kawase T, Aburatani H, Ohki R.

Cancer Sci. 2019 Dec 13. doi: 10.1111/cas.14279. [Epub ahead of print]

2.

Evaluation of the tetrodotoxin uptake ability of pufferfish Takifugu rubripes tissues according to age using an in vitro tissue slice incubation method.

Gao W, Yamada M, Ohki R, Nagashima Y, Tatsuno R, Ikeda K, Kawatsu K, Takatani T, Arakawa O.

Toxicon. 2019 Nov 27;174:8-12. doi: 10.1016/j.toxicon.2019.11.014. [Epub ahead of print]

PMID:
31785287
3.

Nuclear import of IER5 is mediated by a classical bipartite nuclear localization signal and is required for HSF1 full activation.

Yamano S, Kimura M, Chen Y, Imamoto N, Ohki R.

Exp Cell Res. 2020 Jan 1;386(1):111686. doi: 10.1016/j.yexcr.2019.111686. Epub 2019 Nov 6.

PMID:
31669744
4.

Non-naturally Occurring Helical Molecules Can Interfere with p53-MDM2 and p53-MDMX Protein-Protein Interactions.

Su A, Wang S, Sada A, Otani Y, Zhai L, Liu X, Sayama M, Ohki R, Ohwada T.

Chem Pharm Bull (Tokyo). 2019;67(10):1139-1143. doi: 10.1248/cpb.c19-00501.

5.

Overall Shape Constraint of Alternating α/β-Hybrid Peptides Containing Bicyclic β-Proline.

Wang S, Otani Y, Zhai L, Su A, Nara M, Kawahata M, Yamaguchi K, Sada A, Ohki R, Ohwada T.

Org Lett. 2019 Oct 4;21(19):7813-7817. doi: 10.1021/acs.orglett.9b02799. Epub 2019 Sep 13.

PMID:
31518151
6.

Recommendation of long-term and systemic management according to the risk factors in rectal NETs patients.

Kojima M, Chen Y, Ikeda K, Tsukada Y, Takahashi D, Kawano S, Amemiya K, Ito M, Ohki R, Ochiai A.

Sci Rep. 2019 Feb 20;9(1):2404. doi: 10.1038/s41598-018-37707-z.

7.

PHLDA1, another PHLDA family protein that inhibits Akt.

Chen Y, Takikawa M, Tsutsumi S, Yamaguchi Y, Okabe A, Shimada M, Kawase T, Sada A, Ezawa I, Takano Y, Nagata K, Suzuki Y, Semba K, Aburatani H, Ohki R.

Cancer Sci. 2018 Nov;109(11):3532-3542. doi: 10.1111/cas.13796. Epub 2018 Oct 13.

8.

Functional loss of p53 cooperates with the in vivo microenvironment to promote malignant progression of gastric cancers.

Ohtsuka J, Oshima H, Ezawa I, Abe R, Oshima M, Ohki R.

Sci Rep. 2018 Feb 2;8(1):2291. doi: 10.1038/s41598-018-20572-1.

9.

Transcriptionally inducible Pleckstrin homology-like domain, family A, member 1, attenuates ErbB receptor activity by inhibiting receptor oligomerization.

Magi S, Iwamoto K, Yumoto N, Hiroshima M, Nagashima T, Ohki R, Garcia-Munoz A, Volinsky N, Von Kriegsheim A, Sako Y, Takahashi K, Kimura S, Kholodenko BN, Okada-Hatakeyama M.

J Biol Chem. 2018 Feb 9;293(6):2206-2218. doi: 10.1074/jbc.M117.778399. Epub 2017 Dec 12.

10.

Structure-activity relationship study of Aib-containing amphipathic helical peptide-cyclic RGD conjugates as carriers for siRNA delivery.

Wada SI, Takesada A, Nagamura Y, Sogabe E, Ohki R, Hayashi J, Urata H.

Bioorg Med Chem Lett. 2017 Dec 15;27(24):5378-5381. doi: 10.1016/j.bmcl.2017.11.018. Epub 2017 Nov 10.

PMID:
29157863
11.

Pleckstrin homology-like domain family A, member 3 (PHLDA3) deficiency improves islets engraftment through the suppression of hypoxic damage.

Sakata N, Yamaguchi Y, Chen Y, Shimoda M, Yoshimatsu G, Unno M, Sumi S, Ohki R.

PLoS One. 2017 Nov 9;12(11):e0187927. doi: 10.1371/journal.pone.0187927. eCollection 2017.

12.

Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors.

Yamamoto Y, Nagasato M, Rin Y, Henmi M, Ino Y, Yachida S, Ohki R, Hiraoka N, Tagawa M, Aoki K.

Cancer Med. 2017 Oct;6(10):2385-2397. doi: 10.1002/cam4.1185. Epub 2017 Sep 21.

13.

Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.

Nakayama M, Sakai E, Echizen K, Yamada Y, Oshima H, Han TS, Ohki R, Fujii S, Ochiai A, Robine S, Voon DC, Tanaka T, Taketo MM, Oshima M.

Oncogene. 2017 Oct 19;36(42):5885-5896. doi: 10.1038/onc.2017.194. Epub 2017 Jun 19.

14.

A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors.

Takikawa M, Ohki R.

Cancer Sci. 2017 Jun;108(6):1101-1108. doi: 10.1111/cas.13235. Epub 2017 May 22. Review.

15.

Novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells.

Ezawa I, Sawai Y, Kawase T, Okabe A, Tsutsumi S, Ichikawa H, Kobayashi Y, Tashiro F, Namiki H, Kondo T, Semba K, Aburatani H, Taya Y, Nakagama H, Ohki R.

Cancer Sci. 2016 Jun;107(6):734-45. doi: 10.1111/cas.12933. Epub 2016 May 16.

16.

IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis.

Asano Y, Kawase T, Okabe A, Tsutsumi S, Ichikawa H, Tatebe S, Kitabayashi I, Tashiro F, Namiki H, Kondo T, Semba K, Aburatani H, Taya Y, Nakagama H, Ohki R.

Sci Rep. 2016 Jan 12;6:19174. doi: 10.1038/srep19174.

17.

Identification of non-coding RNAs associated with telomeres using a combination of enChIP and RNA sequencing.

Fujita T, Yuno M, Okuzaki D, Ohki R, Fujii H.

PLoS One. 2015 Apr 13;10(4):e0123387. doi: 10.1371/journal.pone.0123387. eCollection 2015.

18.

PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling.

Wang X, Li G, Koul S, Ohki R, Maurer M, Borczuk A, Halmos B.

Oncotarget. 2015 Apr 9;9(38):24914-24926. doi: 10.18632/oncotarget.3674. eCollection 2018 May 18.

19.

PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.

Ohki R, Saito K, Chen Y, Kawase T, Hiraoka N, Saigawa R, Minegishi M, Aita Y, Yanai G, Shimizu H, Yachida S, Sakata N, Doi R, Kosuge T, Shimada K, Tycko B, Tsukada T, Kanai Y, Sumi S, Namiki H, Taya Y, Shibata T, Nakagama H.

Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):E2404-13. doi: 10.1073/pnas.1319962111. Epub 2014 May 27.

20.

Central retinal vein occlusion in a pediatric patient with SLE and antiphospholipid antibodies without anti-cardiolipin or anti-β2 glycoprotein I antibodies.

Korematsu S, Goto H, Gotoh C, Ohki R, Kubota T, Izumi T.

BMC Pediatr. 2014 May 3;14:116. doi: 10.1186/1471-2431-14-116.

21.

Suicide attempt with an overdose of sunitinib.

Arai S, Matsui H, Ohki R, Miyazawa Y, Koike H, Hashita T, Katsuyama Y, Sekine Y, Nomura M, Shibata Y, Hatori M, Ito K, Yamamoto K, Ohmori S, Suzuki K.

Br J Clin Pharmacol. 2014 Oct;78(4):933-5. doi: 10.1111/bcp.12381. No abstract available.

22.

Identification of telomere-associated molecules by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP).

Fujita T, Asano Y, Ohtsuka J, Takada Y, Saito K, Ohki R, Fujii H.

Sci Rep. 2013 Nov 8;3:3171. doi: 10.1038/srep03171.

23.

Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein.

Ozeki C, Sawai Y, Shibata T, Kohno T, Okamoto K, Yokota J, Tashiro F, Tanuma S, Sakai R, Kawase T, Kitabayashi I, Taya Y, Ohki R.

J Biol Chem. 2011 May 20;286(20):18251-60. doi: 10.1074/jbc.M110.208587. Epub 2011 Mar 28.

24.

Identification and characterization of a novel multidrug resistance operon, mdtRP (yusOP), of Bacillus subtilis.

Kim JY, Inaoka T, Hirooka K, Matsuoka H, Murata M, Ohki R, Adachi Y, Fujita Y, Ochi K.

J Bacteriol. 2009 May;191(10):3273-81. doi: 10.1128/JB.00151-09. Epub 2009 Mar 13.

25.

PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt.

Kawase T, Ohki R, Shibata T, Tsutsumi S, Kamimura N, Inazawa J, Ohta T, Ichikawa H, Aburatani H, Tashiro F, Taya Y.

Cell. 2009 Feb 6;136(3):535-50. doi: 10.1016/j.cell.2008.12.002.

26.

p53 target gene AEN is a nuclear exonuclease required for p53-dependent apoptosis.

Kawase T, Ichikawa H, Ohta T, Nozaki N, Tashiro F, Ohki R, Taya Y.

Oncogene. 2008 Jun 19;27(27):3797-810. doi: 10.1038/onc.2008.32. Epub 2008 Feb 11.

PMID:
18264133
27.

Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis.

Ohki R, Kawase T, Ohta T, Ichikawa H, Taya Y.

Cancer Sci. 2007 Feb;98(2):189-200. Erratum in: Cancer Sci. 2007 Mar;98(3):464.

28.

Bilateral optic neuropathy associated with multiple myeloma.

Shimada Y, Shibuya M, Ohki R, Yoneya S, Nakamura Y.

J Neuroophthalmol. 2006 Jun;26(2):117-20.

PMID:
16845312
29.
30.

Gene expression profiling of human atrial myocardium with atrial fibrillation by DNA microarray analysis.

Ohki R, Yamamoto K, Ueno S, Mano H, Misawa Y, Fuse K, Ikeda U, Shimada K.

Int J Cardiol. 2005 Jul 10;102(2):233-8.

PMID:
15982490
31.
32.
33.

Bacillus subtilis LmrA is a repressor of the lmrAB and yxaGH operons: identification of its binding site and functional analysis of lmrB and yxaGH.

Yoshida K, Ohki YH, Murata M, Kinehara M, Matsuoka H, Satomura T, Ohki R, Kumano M, Yamane K, Fujita Y.

J Bacteriol. 2004 Sep;186(17):5640-8.

34.

Transcriptional profile of genes induced in human atrial myocardium with pressure overload.

Ohki R, Yamamoto K, Ueno S, Mano H, Misawa Y, Fuse K, Ikeda U, Shimada K.

Int J Cardiol. 2004 Sep;96(3):381-7.

PMID:
15301891
35.

Telomere-bound TRF1 and TRF2 stall the replication fork at telomeric repeats.

Ohki R, Ishikawa F.

Nucleic Acids Res. 2004 Mar 8;32(5):1627-37. Print 2004.

36.

Molecular mechanisms of DNA end-loop formation by TRF2.

Yoshimura SH, Maruyama H, Ishikawa F, Ohki R, Takeyasu K.

Genes Cells. 2004 Mar;9(3):205-18.

37.

DNA microarray analysis of natural killer cell-type lymphoproliferative disease of granular lymphocytes with purified CD3-CD56+ fractions.

Choi YL, Makishima H, Ohashi J, Yamashita Y, Ohki R, Koinuma K, Ota J, Isobe Y, Ishida F, Oshimi K, Mano H.

Leukemia. 2004 Mar;18(3):556-65.

PMID:
14737071
38.

Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas.

Koinuma K, Shitoh K, Miyakura Y, Furukawa T, Yamashita Y, Ota J, Ohki R, Choi YL, Wada T, Konishi F, Nagai H, Mano H.

Int J Cancer. 2004 Jan 10;108(2):237-42.

39.

Effects of olmesartan, an angiotensin II receptor blocker, on mechanically-modulated genes in cardiac myocytes.

Ohki R, Yamamoto K, Ueno S, Mano H, Ikeda U, Shimada K.

Cardiovasc Drugs Ther. 2003 May;17(3):231-6.

PMID:
14574081
40.

DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome.

Ueda M, Ota J, Yamashita Y, Choi YL, Ohki R, Wada T, Koinuma K, Kano Y, Ozawa K, Mano H.

Br J Haematol. 2003 Oct;123(2):288-96.

PMID:
14531911
41.

DNA microarray analysis of hematopoietic stem cell-like fractions from individuals with the M2 subtype of acute myeloid leukemia.

Oshima Y, Ueda M, Yamashita Y, Choi YL, Ota J, Ueno S, Ohki R, Koinuma K, Wada T, Ozawa K, Fujimura A, Mano H.

Leukemia. 2003 Oct;17(10):1990-7.

PMID:
14513049
42.

Proteomic analysis of hematopoietic stem cell-like fractions in leukemic disorders.

Ota J, Yamashita Y, Okawa K, Kisanuki H, Fujiwara S, Ishikawa M, Lim Choi Y, Ueno S, Ohki R, Koinuma K, Wada T, Compton D, Kadoya T, Mano H.

Oncogene. 2003 Aug 28;22(36):5720-8.

PMID:
12944923
43.

The BceRS two-component regulatory system induces expression of the bacitracin transporter, BceAB, in Bacillus subtilis.

Ohki R, Giyanto, Tateno K, Masuyama W, Moriya S, Kobayashi K, Ogasawara N.

Mol Microbiol. 2003 Aug;49(4):1135-44.

44.

DNA microarray analysis of in vivo progression mechanism of heart failure.

Ueno S, Ohki R, Hashimoto T, Takizawa T, Takeuchi K, Yamashita Y, Ota J, Choi YL, Wada T, Koinuma K, Yamamoto K, Ikeda U, Shimada K, Mano H.

Biochem Biophys Res Commun. 2003 Aug 8;307(4):771-7.

PMID:
12878176
45.

Screening of genes specifically activated in the pancreatic juice ductal cells from the patients with pancreatic ductal carcinoma.

Yoshida K, Ueno S, Iwao T, Yamasaki S, Tsuchida A, Ohmine K, Ohki R, Choi YL, Koinuma K, Wada T, Ota J, Yamashita Y, Chayama K, Sato K, Mano H.

Cancer Sci. 2003 Mar;94(3):263-70.

46.

Woman with postpartum ventricular tachycardia and hypomagnesemia.

Onagawa T, Ohkuchi A, Ohki R, Izumi A, Matsubara S, Sato I, Suzuki M, Minakami H.

J Obstet Gynaecol Res. 2003 Apr;29(2):92-5.

PMID:
12755529
47.

Multidrug resistant phenotype of Bacillus subtilis spontaneous mutants isolated in the presence of puromycin and lincomycin.

Murata M, Ohno S, Kumano M, Yamane K, Ohki R.

Can J Microbiol. 2003 Feb;49(2):71-7.

PMID:
12718394
48.

Instability of sensory histidine kinase mRNAs in Escherichia coli.

Aiso T, Ohki R.

Genes Cells. 2003 Feb;8(2):179-87.

49.
50.

A bacitracin-resistant Bacillus subtilis gene encodes a homologue of the membrane-spanning subunit of the Bacillus licheniformis ABC transporter.

Ohki R, Tateno K, Okada Y, Okajima H, Asai K, Sadaie Y, Murata M, Aiso T.

J Bacteriol. 2003 Jan;185(1):51-9.

Supplemental Content

Support Center